Robert Beecroft is listed as an executive officer and director on 3 SEC Form D filings by 1 issuer between Aug 2017 and Oct 2018: ImmunoPrecise Antibodies Ltd. (Victoria, British Columbia, Canada (as filed: A1) — pharmaceuticals — 2017–2018; $2M reported sold to 7 investors).
What this means One deal on file with the SEC. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Greg Smith (3 shared filings), James Kuo (3 shared filings), Natasha Tsai (3 shared filings), Guy Champagne (2 shared filings), Jennifer Bath (2 shared filings) and 3 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Robert. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — 9 court cases matching the name, 4 bankruptcy cases matching the name listed in Key records below.
What this means 13 records came back, including 1 court case still open — open cases can take years and cost money. Each one is listed below with a link to the original document and a line saying why it matched. A name match is not proof it is the same person or company — read the why line and the document. Being sued or named in a release is an accusation, not a finding.
We compared 3 public filings for Robert Beecroft and found 3 differences: Form D filed 21 days after the first sale; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.